Clearance Summary
RABBITT ANTISERUM TO HUMAN C3C received FDA 510(k) clearance under submission number K831905, sponsored by Dako Corp.. The device was reviewed via the Traditional premarket notification pathway and assigned to the Immunology review panel. The statutory decision date of record is 1983-07-18.
- Submission: K831905
- Applicant / Sponsor: Dako Corp.
- Clearance pathway: Traditional
- Review panel: Immunology
- Device class: Class II
- Regulation citation: 21 CFR 866.5240
- Decision date: 1983-07-18
Classification & Regulation
This clearance is catalogued under FDA product code CZW and 21 CFR 866.5240, within the Immunology review panel as a Class II device.